MIM
BCAB icon

MetLife Investment Management’s BioAtla BCAB Stock Holding History

MetLife Investment Management’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-500
Closed -$74.9K – 2902
2023
Q2 		$74.9K Buy
+500
New +$86K ﹤0.01% 2826
2022
Q1 		– Sell
-100
Closed -$97.7K – 2735
2021
Q4 		$97.7K Hold
100
– – ﹤0.01% 2413
2021
Q3 		$147K Hold
100
– – ﹤0.01% 2264
2021
Q2 		$211K Hold
100
– – ﹤0.01% 2139
2021
Q1 		$253K Buy
+100
New +$256K ﹤0.01% 1924

Other funds holding BCAB

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's BCAB Position: Q3 2023 in Review

MetLife Investment Management sold out of BioAtla (BCAB) in Q3 2023, closing a stake of 500 shares — an estimated $74.9K sold.

MetLife Investment Management first reported a position in BCAB in Q1 2021 and held it in 5 quarters. The position peaked at $253K in Q1 2021. 82 funds tracked by Wall St. Rank hold BCAB as of Q3 2023.

  • MetLife Investment Management reported no remaining BioAtla position as of Q3 2023 after selling out during the quarter.
  • MetLife Investment Management sold 500 BioAtla shares in Q3 2023, an estimated $74.9K.
  • MetLife Investment Management first reported a position in BioAtla in Q1 2021 and held it in 5 quarters.
  • MetLife Investment Management's BioAtla position peaked at $253K in Q1 2021.
  • 82 funds tracked by Wall St. Rank held BioAtla as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.